Stone-Free Living: How Active Removal Can Improve Quality of Life for Patients with Poor Performance Status
"Navigating urolithiasis when health is already compromised? Discover how proactive stone management can make a difference."
As the global population ages, the prevalence of urolithiasis, or urinary stone disease, is on the rise, especially among individuals with compromised health. The intersection of urolithiasis and poor performance status (PS) presents a unique challenge, with treatment decisions complicated by concerns about life expectancy and perioperative risks. For those already struggling with health issues, the added burden of kidney stones can severely diminish their quality of life.
Traditionally, there has been a debate about whether active stone removal is appropriate for patients with poor PS. Active intervention comes with its own set of risks, including complications related to comorbidities, decreased immune function, and the limitations of surgical positioning. This has led to some practitioners favoring conservative management, focusing on symptom relief rather than active removal.
However, emerging research suggests that active stone removal can offer significant benefits, not only in alleviating immediate symptoms but also in improving overall and stone-specific survival rates. This article explores the latest findings on active stone removal in patients with poor PS, offering insights into how proactive management can lead to better outcomes and enhanced quality of life.
Kidney Stone Burden and Guidance
Urolithiasis, also called urinary stone disease, kidney stones, or nephrolithiasis, involves stones forming in the kidneys and/or bladder and can cause symptoms such as pain and hematuria. Risk factors reported in the 2024 Urologic Diseases in America Annual Data Report include family history, certain medical conditions, and diet. A 2022 analysis used Global Burden of Disease data for 1990–2019 to examine age-standardized incidence, deaths, and disability-adjusted life years across 21 regions and 204 countries. A 2024 review noted that the studies it identified on incidence, mortality, and DALYs all predated the COVID-19 pandemic, limiting what they show about more recent trends.
Guideline-Based Stone Care
Urological organizations publish evidence-based guidance for managing urolithiasis, and the AUA and EAU guidelines are among those used by clinicians. The EAU guidance covers stone classification, diagnostic evaluation, disease management, and recurrence prevention. The AUA medical-management guideline describes using metabolic testing and close follow-up to guide medical and dietary therapy for high-risk or interested stone-forming patients, with the aim of reducing recurrence. These sources describe established approaches but do not provide specific limitations or comparative outcome figures in the supplied material.
Why Active Stone Removal Matters: More Than Just Symptom Relief
A recent study published in BMC Urology investigated the outcomes of active stone removal versus conservative management in patients with poor PS. The study retrospectively reviewed data from 74 patients with Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4, all treated for upper urinary tract calculi.
- Improved Survival Rates: Patients who underwent active stone removal demonstrated significantly higher two-year overall survival rates (88.0%) compared to those managed conservatively (38.4%). This difference underscores the potential life-extending benefits of proactive intervention.
- Enhanced Stone-Specific Survival: The active removal group also exhibited superior two-year stone-specific survival rates (100.0%) compared to the conservative management group (61.3%). This indicates that active removal not only prolongs life but also specifically addresses the risks associated with urolithiasis.
- Effective Stone Clearance: The surgical treatment group achieved an overall stone-free rate of 78.8%, demonstrating the effectiveness of active removal techniques.
Active Removal in Older and Poor-Status Patients
A report titled “Active stone removal is a safe option for octogenarians and nonagenarians with nephrolithiasis” cites Yamashita et al., who reported a stone-free rate (SFR) of 50% after PCNL among patients with poor performance status and a mean age of 82 years; the SFR after URS in their series was up to 87%. A separate study identified 56 patients with performance status 3 or 4 admitted to Kishiwada Tokushukai Hospital between April 2019 and March 2025 for septic shock due to obstructive pyelonephritis caused by a urinary tract stone. The supplied snippet for that study describes its patient group and setting, but does not provide its findings.
Benefits Depend on Perioperative Risk
A study of upper urinary tract stone disease in patients with poor performance status acknowledged limitations but reported that active stone removal could be performed safely in its study population. It also reported longer survival and infrequent stone-related events among patients who received active interventions, provided perioperative risks were assessed and managed carefully. This finding supports a qualified case for intervention, rather than a claim that active removal is appropriate regardless of individual risk. The supplied review snippets describe urolithiasis as recurrent and potentially associated with complications, but do not provide comparative evidence that resolves treatment trade-offs for poor-performance-status patients.
Treatment Comparisons and Individualization
A study of complex renal calculi treated with low-power holmium laser mini-percutaneous nephrolithotomy reported a mean surgery duration of 85 minutes, with a range of 60–120 minutes, and an 87.09% stone-free rate (27 of 31) at the end of the session. An editorial describes a direct comparison of flexible ureteroscopy using a flexible, navigable suction ureteral access sheath with mini-percutaneous nephrolithotripsy for impacted upper ureteral stones, framing it as evidence relevant to choosing between retrograde and antegrade approaches. The supplied excerpts do not report that comparison’s results, so they do not establish which approach is superior. A review excerpt says treatment strategies are tailored to factors including stone size, composition, location, and underlying metabolic conditions.
Making Informed Decisions: A Path Forward
The decision to pursue active stone removal in patients with poor PS is complex and multifactorial. It requires careful consideration of the patient's overall health, comorbidities, and individual preferences. However, the evidence suggests that active intervention can offer significant benefits in terms of survival and quality of life. By embracing a proactive approach and leveraging advanced stone removal techniques, healthcare providers can empower patients with poor PS to live more comfortably and extend their years. It is imperative that medical professionals continue to investigate and refine treatment strategies, ensuring that every patient receives the best possible care tailored to their unique circumstances. Further studies, especially randomized controlled trials, are needed to solidify these findings and guide clinical practice.
Stone Analysis and Management
An EULIS-supported online survey conducted in October 2022 examined stone-analysis practices and perspectives among urologists and residents worldwide. The survey was completed by 351 urologists (75.4%) and 115 residents (24.7%). In the reported results, 49.1% considered stone analysis of utmost importance for every patient, 91.8% believed it changes kidney stone disease management, and 62.3% said they adhered to guidelines. These figures reflect respondents’ views and reported practices, rather than patient outcomes.
Emerging Directions in Urolithiasis Care
A 2026 review describes current diagnostic approaches, modern therapeutic interventions, prevention strategies, and future innovations in urolithiasis management. It anticipates that combining advanced technologies with evidence-based clinical practice may enhance treatment efficacy, reduce recurrence, and improve patient care. Another review identifies personalized medicine, targeted drug-delivery systems, and a growing understanding of genetic and metabolic contributors to stone formation as promising directions. These are described as emerging possibilities, not established clinical outcomes.
Pain, Symptoms, and Diagnosis
A 2024 Siddha medicine case-report abstract describes urolithiasis symptoms including renal colic, flank pain, blood in the urine, urinary obstruction, urinary tract infections, dysuria, hydronephrosis, nausea, and vomiting. An educational case identifies noncontrast CT as the gold standard for diagnosing urinary stones in the discussed differential diagnosis. It notes that ultrasound or an abdominal kidney–ureter–bladder radiograph may be used in some cases, while the snippet cautions that operator experience may matter. The supplied material presents these as clinical and diagnostic descriptions, not as evidence about quality-of-life outcomes after active removal.